ASX Announcement September 2026 Quarterly Activities Report Highlights ? Analytical Validation in progress following receipt of ?rst batch of test kits ? Statement of Work executed with CLIA-certi?ed U.S. laboratory, Asuragen, to undertake the pivotal Clinical Validation testing program ? Screening...
Quarterly activities and cashflow report
Filed with ASX ·
6ix is reading this filing.
Earlier from CLEO Diagnostics
- CLEO Screening Test Meets Rigorous Performance Targets
- CLEO Commences Analytical Validation Ahead of FDA Submission
- Cleo Files Patents for its Ovarian Cancer Screening Test
- CLEO Commences Ovarian Cancer Screening Test Development
- CLIA Certified Lab selected - Pivotal US Clinical Validation
